We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Biosimilar enough

24 May 2018 By Robert Cyran

Seven of the ten best-selling U.S. drugs, including arthritis therapy Humira, have lost their main patent or will soon do so. Rivals hoping to duplicate these so-called biologics face a thicket of legal and market curbs. But a determined FDA may soon slash a path to lower prices.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)